

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

UNIVERSITY OF UTAH,

Plaintiff,

v.

MAX-PLANCK-GESELLSCHAFT zur  
FORDERUNG der WISSENSCHAFTEN e.V.,  
a corporation organized under the laws of  
Germany; MAX-PLANCK-INNOVATION  
GmbH, a corporation organized under the laws  
of Germany; WHITEHEAD INSTITUTE FOR  
BIOMEDICAL RESEARCH, a Delaware  
corporation; MASSACHUSETTS INSTITUTE  
OF TECHNOLOGY, a Massachusetts  
corporation; ALNYLAM  
PHARMACEUTICALS INC., a Delaware  
corporation; and ROBERT L. CARET,  
President of the University of Massachusetts in  
his official capacity; JAMES R. JULIAN,  
Executive Vice President and Chief Operating  
Officer of the University of Massachusetts, in  
his official capacity; CHRISTINE M. WILDA,  
Senior Vice President for Administration,  
Finance & Technology and University  
Treasurer of the University of Massachusetts,  
in her official capacity; and JAMES P.  
MCNAMARA, Executive Director, Office of  
Technology Management of the University of  
Massachusetts, in his official capacity, their  
predecessors and successors in office,

C.A. No. 1:11-cv-10484

Defendants.

**DEFENDANTS' ACKNOWLEDGMENT OF SATISFACTION OF JUDGMENT**

Defendants Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Max-Planck-Innovation GmbH; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Alnylam Pharmaceuticals, Inc.; Robert L. Caret; James R. Julian, Jr.; Christine M. Wilda; and James P. McNamara (collectively, "Defendants"), by and through their counsel of record, hereby acknowledge and agree that the Amended Judgment entered by The Honorable Patti B. Saris in this civil action, C.A. No. 1:11-cv-10484, against the plaintiff University of Utah on September 6, 2017 at Docket No. 286, a copy of which is attached hereto as Exhibit A, has been and is **FULLY AND FINALLY SATISFIED**.

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Max-Planck-Innovation GmbH; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; and Alnylam Pharmaceuticals, Inc. By their attorneys,

Of counsel:

Morgan Chu (CA Bar # 70446)  
David I. Gindler (CA Bar # 117824)  
Alan J. Heinrich (CA Bar # 212782)  
IRELL & MANELLA LLP  
1800 Avenue of the Stars, Suite 900  
Los Angeles, California 90067-4276  
(310) 277-1010  
mchu@irell.com  
dgindler@irell.com  
aheinrich@irell.com

Sandra Haberny (CA Bar # 260977)  
IRELL & MANELLA LLP  
840 Newport Center Drive, Suite 400  
Newport Beach, CA 92660  
(949) 760-0991  
shaberny@irell.com

Thomas F. Maffei (BBO 313220)  
Sherin & Lodgen LLP  
101 Federal Street, Boston, MA 02110  
(617) 646-2000

DATED: October 17, 2017

/s/ Thomas F. Maffei

Thomas F. Maffei (BBO 313220)  
Sherin & Lodgen LLP  
101 Federal Street, Boston, MA 02110  
(617) 646-2000

ROBERT L. CARET, President of the University of Massachusetts, in his official capacity; JAMES R. JULIAN, Executive Vice President and Chief Operating Officer of the University of Massachusetts, in his official capacity; CHRISTINE M. WILDA, Senior Vice President for Administration, Finance & Technology and University Treasurer of the University of Massachusetts, in his official capacity; and JAMES P. MCNAMARA, Executive Director, Office of Technology Management of the University of Massachusetts, in his official capacity

By their attorney,

Maura Healey  
Attorney General for the Commonwealth of Massachusetts

/s/ David I. Gindler

David I. Gindler (CA Bar # 117824)  
Special Assistant Attorney General  
IRELL & MANELLA LLP  
1800 Avenue of the Stars, Suite 900  
Los Angeles, California 90067-4276  
(310) 277-1010  
dgindler@irell.com

**CERTIFICATE OF SERVICE**

I, Thomas F. Maffei, hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) on October 17, 2017.

/s/ Thomas F. Maffei  
Thomas F. Maffei